BioSpace News Archive

Valneva SE reported its consolidated financial results for the year ending December 31, 2023 and provided several key corporate updates.

So-Young International Inc. announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023.

BioNTech SE reported financial results for the three months and full year ended December 31, 2023, and provided an update on its corporate progress.

Avid Bioservices, Inc. announced it received a notice on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250 as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024 in a timely manner.

ACELYRIN, INC today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.

BioLineRx Ltd. today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.

OKYO Pharma Limited announces that it will be releasing new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on March 22, 2024.

Johnson Matthey Plc (JM) announces that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

LAVA Therapeutics N.V. today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2023.

Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts.